SynthesisFrontiers in oncology2025
Frontiers and hot topics in tumor metabolic reprogramming: a bibliometric analysis from 2014 to 2023.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbial metabolites in tumor metabolic reprogramming and immunotherapy: new insights.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor metabolic reprogramming refers to the alteration of metabolic pathways and patterns by tumor cells to adapt to various environmental conditions and energy demands, thereby playing a pivotal role in tumor progression. Targeting tumor metabolism has been shown to exert anti-tumor effects and improve the efficacy of conventional cancer therapies. As a result, tumor metabolic reprogramming has become a research area of considerable clinical value and potential, warranting comprehensive investigation. Methods: This bibliometric analysis was conducted to systematically summarize the research status, hotspots, and future trends in the field of tumor metabolic reprogramming. Relevant publications from January 1, 2014, to December 31, 2023, were retrieved from the Web of Science Core Collection. A total of 7,311 publications authored by 41,735 researchers from 5,967 institutions in 104 countries/regions were included. Bibliometric analysis and visualization were performed using VOSviewer, CiteSpace, and the bibliometrix R package. Results: Keyword co-occurrence analysis revealed six major research clusters: tumor microenvironment, various cancers, pathological processes, major mechanisms, epigenetics, and mitochondria. The top three frequently occurring keywords were glycolysis, tumor microenvironment, and mitochondria. China was the most productive country (2,966 publications), followed by Fudan University as the most productive institution (216 publications), and Liu Yang as the most prolific author (40 publications). Conclusion: Research on tumor metabolic reprogramming has shown rapid global growth and demonstrates significant clinical importance and application potential, especially in the context of breast cancer..
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.